Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI and Carboplatin in GEP-NEC
NCT05385861Phase 2Enrolling by invitation
- Sponsor
- National Health Research Institutes
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by National Health Research Institutes. Primary endpoints: Maximum Tolerated Dose at 3 years, Recommended Phase 2 Dose at 3 years and 1 more. Started Aug 2025; status: enrolling by invitation.
02
Drugs
irinotecan liposome injection
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on NCT05385861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385861.